Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. This study examined potential genetic markers associated with response and PFS in the phase I study of dabrafe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2013-09, Vol.19 (17), p.4868-4878
Hauptverfasser:	NATHANSON, Katherine L, MARTIN, Anne-Marie, MILLWARD, Michael, BROWN, Michael P, PAVLICK, Anna, DAVIES, Michael A, BO MA, GAGNON, Robert, CURTIS, Martin, LEBOWITZ, Peter F, KEFFORD, Richard, LONG, Georgina V, WUBBENHORST, Bradley, GRESHOCK, Joel, LETRERO, Richard, D'ANDREA, Kurt, O'DAY, Steven, INFANTE, Jeffrey R, FALCHOOK, Gerald S, ARKENAU, Hendrik-Tobias
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Comparative Genomic Hybridization Cyclin D1 - genetics Cyclin-Dependent Kinase Inhibitor p16 - genetics Dermatology Disease Progression Disease-Free Survival DNA Copy Number Variations - genetics Humans Imidazoles - administration & dosage Medical sciences Melanoma - drug therapy Melanoma - genetics Melanoma - pathology Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation Neoplasm Staging Oximes - administration & dosage Pharmacology. Drug treatments Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics PTEN Phosphohydrolase - genetics Tumors Tumors of the skin and soft tissue. Premalignant lesions
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!